Body dysmorphic-induced Androgenic Anabolic Steroids usage and its association with mental health outcomes ========================================================================================================== * Ahmed Gawash * Hasan Zia * David F. Lo ## Abstract This systematic review aims to examine the relationship between body dysmorphic disorder (BDD), anabolic-androgenic steroid (AAS) use, and mental health outcomes. Previous research has suggested that individuals with BDD may be more likely to abuse AAS due to their preoccupation with appearance, but AAS use may worsen mental health issues in this population. The review will also consider potential interventions and treatments that may help mitigate the detrimental effects of AAS use in individuals with BDD. The review will include only published literature and will utilize electronic databases from a variety of databases such as PubMed, Scopus, Embase, and PsycINFO. Two reviewers independently screened studies for inclusion, extract data, and assessed the quality of the evidence. The findings of this review will provide important insights into the complex relationship between BDD, AAS use, and mental health outcomes, and will inform the development of effective interventions and treatments for individuals with BDD who may be considering AAS use. Keywords * anabolic-androgenic steroids * doping * mood disorders * body dysmorphia * mental health ## Introduction Body dysmorphic disorder (BDD) is a psychiatric disorder characterized by an excessive and distorted preoccupation with one or more perceived physical defects or flaws in appearance that are not observable or appear minor to others (1). These preoccupations may cause significant distress or impairment in social, occupational, or other important areas of functioning. Individuals with BDD may engage in repetitive behaviors, such as mirror checking, skin picking, or seeking reassurance from others, in an attempt to alleviate their distress (1)(2). BDD is a relatively common disorder that can occur in both males and females and tends to develop in adolescence or early adulthood. It is often accompanied by other mental health conditions, such as anxiety and depression (3)(4) A class of synthetic hormones called anabolic-androgenic steroids (AAS), also referred to as steroids or anabolic steroids, are derived from the hormone testosterone, which is produced naturally in the human body. AAS are frequently used by athletes and bodybuilders for performance-enhancing purposes in order to increase muscle size and strength (5). However, AAS can also be abused by individuals with body dysmorphic disorder BDD, who may use them in an attempt to alter their appearance and alleviate distress related to their perceived physical defects or flaws (6). Using AAS can have serious negative health effects, including liver damage, kidney damage, and an increased risk of heart attack or stroke (7). AAS use can also cause psychological effects, such as mood swings, aggression, and psychosis (8). The abuse of AAS is strictly regulated in many countries, and possession, distribution, and use of these drugs without a prescription is illegal in many jurisdictions. The relationship between BDD, AAS use, and mental health outcomes is complicated and involves multiple factors. While some individuals with BDD may turn to AAS as a means of improving their perceived physical flaws, research has shown that AAS use may actually worsen mental health issues in individuals with BDD, rather than improving them. This may be due to the physical and hormonal changes that occur with AAS use, as well as the psychological effects of the drugs, and the intensification of the preoccupation with appearance that is characteristic of BDD (9). Examining this relationship is crucial for understanding the underlying issues and alleviating detrimental mental health outcomes in those who have BDD and are considering using, or concurrently taking AAS. This systematic review aims to further explore the relationship between BDD, AAS use, and mental health outcomes, and to consider potential interventions and future treatments that may help mitigate these detrimental effects. ## Methods This systematic review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline, registered with PROSPERO International Prospective Register of Systematic Reviews. ### Inclusion Criteria The inclusion criteria included articles from within the last 50 years but the earliest paper utilized in the study was published in 1992. The inclusion criteria for this systematic review were as follows: (1) any article containing primary data on the usage of AAS by individuals with BDD and its association with mental health outcomes was included for analysis; (2) specific mental health outcomes examined included depression, anxiety, and BDD symptom severity; (3) comparison measures included the use of other substances and no substance use; (4) types of publication included in the analysis included case studies and series, single- and double-arm clinical trials, and retrospective analysis; (5) participants included in the analysis were those diagnosed with body dysmorphic disorder and a history of androgenic anabolic steroid usage; and (6) studies published in any language were included in the analysis. ### Exclusion Criteria Exclusion criteria included studies that were not relevant to the topic, studies of poor quality, and studies outside the specified time frame. If the study design was unclear from the title or abstract review, the full text was then reviewed for eligibility. No limitations were placed on the types of studies included. ### Search Strategy A systematic search of the literature was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A comprehensive search was performed using the electronic databases CINAHL, Embase, PsychINFO, PubMed, and Scopus, with a focus on studies published between January 1, 1973, and January 1, 2023. The search strategy employed a combination of medical subject headings (MeSH) and boolean operators were applied. Search terms were based on key concepts such as “AAS” AND “mental health outcomes” AND “body dysmorphia”, and appropriate variants. Additionally, references of included studies were also evaluated for inclusion. ### Data Extraction After completing the initial screening process, eligible studies were further evaluated for data collection. Two reviewers independently performed a full-text appraisal and extracted the relevant information onto a data sheet. The extracted data focused on the relationship between anabolic-androgenic steroid (AAS) use and symptoms of body dysmorphic disorder (BDD). The reviewers also checked the relevance and accuracy of data reporting. The research quality, data reliability, and generalizability were also evaluated during this process to ensure the credibility of the extracted data. A standardized data extraction form was used to ensure consistency and completeness of the extracted data, and any discrepancies in the data extraction process were resolved through discussion and consensus between the two reviewers. ## Results The database query resulted in 39 articles. After removing duplicates, 35 articles remained. After a full-text appraisal of the remaining articles, 31 articles remained (Table 1). The date of publication of studies included ranged from 1992 to 2022. View this table: [Table 1.](http://medrxiv.org/content/early/2023/01/17/2023.01.14.23284562/T1) Table 1. PRISMA Reporting Guideline Psychiatric disorder known as body dysmorphic disorder (BDD) is characterized by obsession with alleged physical flaws. BDD affects men and women equally, according to prior studies (10). According to research by Jenkins et al., BDD sufferers may be more likely to abuse steroids in an effort to enhance their appearance. Bodybuilders and fitness athletes’ research into the effects of lockdown on physical activity and mental health among (BoFA) participants revealed a marked decline in both during the lockdown. BoFA also noted that during the lockdown, they experienced a high level of insomnia, depression, and anxiety. The study discovered that BoFA members’ financial worries increased during the lockdown, with about 32% of them depending on their athletic endeavors for income. BoFA also scored highly on measures of depression, insomnia, and anxiety, which may be due to the loss of the protective effect of physical activity on mental health or the psychological impact of being unable to train (11). Finally, the study found that individuals at risk for muscle dysmorphia performed worse and scored higher on tests of anxiety, insomnia, and depression compared to those without the disorder (11). Given that many of the underlying causes of male morbidity and mortality are avoidable health behaviors, lifestyle medicine is crucial to men’s health (12). In order to effectively address men’s health issues and decrease the use of anabolic steroids as a coping mechanism, it is crucial to understand how gender socialization and masculinity affect men’s health risk and protective behaviors. Alongside everyday health risk factors, the COVID-19 pandemic has had a significant impact on mental health, with many people experiencing increased levels of stress, anxiety, and isolation (13). Previous studies have demonstrated that people with body dysmorphic disorder (BDD) have been negatively impacted by pandemic-related stress (14,15). As many as 2.2% of adolescents and 7.4% of adult and adolescent psychiatric inpatients have been found to have BDD (15). Because people may use substances or unhealthy behaviors to cope with the increased stress and uncertainty, these factors can increase the risk of substance use and BDD. Furthermore, one factor that may contribute to an increased risk of substance use and BDD during the pandemic is the increased reliance on social media and online interactions. Zaami et al. has shown that the use of social media is linked to an increased risk of negative body image and disordered eating behaviors (13), and the pandemic has likely led to an even greater reliance on these platforms for social connection and communication. People who identify as members of sexual minorities may be especially susceptible to muscle dysmorphia and other types of body dysmorphic disorder (BDD) during the pandemic due to the additional stressors and challenges posed by stigma and discrimination, according to Nagata et al. Muscle dysmorphia, disordered eating attitudes, use of performance-enhancing drugs, and problems with body image have all been found to be more prevalent in people who have more sexual partners, are older, and have higher levels of eating concern and impulsivity (17,18,19,20). Nagata et al. also discovered that having more sexual partners is linked to higher levels of body dysmorphia and muscle dysmorphia in both men and women. This might be as a result of how society’s standards for physical and sexual attractiveness affect people’s perceptions of their bodies and their self-worth (17). Age is linked to higher levels of muscle dysmorphia and body image disturbance, according to research by Strubel et al. (18). This might be because maintaining a youthful appearance is valued and because aging can have an impact on physical appearance. Muscle dysmorphia and disordered eating attitudes have also been associated with higher levels of impulsivity and eating concern (19). These characteristics might help people develop negative body-image and weight-management habits. Additionally, Hildebrandt et al. investigated the factors that may be related to the use of appearance- and performance-enhancing drugs (APEDS) in a group of young males and discovered that APEDS were widely used among this group, with a higher prevalence among those who had a strong desire for more muscle and those who identified as LGBTQ+ individuals (21). Dietary restriction, binge eating, and vomiting are examples of eating disorder symptoms that were also linked to the use of APEDS. The link between APEDS use and eating disorder symptoms, however, vanished when the drive for muscularity was taken into account, indicating that the drive for muscularity may be a more significant predictor of APEDS use in this population. In comparison to non-users, participants using APEDS scored higher on measures of drive for muscularity and body appreciation but lower on drive for leanness. These findings emphasize the significance of understanding the various elements that may lead to muscle dysmorphia, disordered eating behaviors, and other disturbances of body image. The emergence of mood disorders is one of the main ways that AAS use can worsen mental health outcomes. The use of AAS has been associated with a higher risk of depression, mania, and other bipolar disorders. One possible side effect of using steroids is depression, especially if taken in high doses or for an extended period of time. The signs of steroid-induced depression can include feeling down or hopeless, losing interest in once-enjoyable activities, changing one’s appetite or sleep schedule, having trouble concentrating, and feeling guilty or unworthy. This could be brought on by how AAS affects brain chemistry and neurotransmitter activity (22). This alteration in brain chemistry has the potential to cause substantial changes in mood and emotional state, which may further promote the emergence of mood disorders. Another way in which AAS use can worsen mental health outcomes is through the development of psychotic symptoms. Use of AAS has been linked to a higher risk of psychosis, including delusions and hallucinations. This might be brought on by the way that AAS alter brain structure and function, especially in regions connected to mood and cognition (22). In addition to raising the risk of mood and psychotic disorders, using AAS can also make people more vulnerable to anxiety and other types of stress. This could be as a result of how AAS affect the body’s stress response system as well as potential psychological and social stresses linked to AAS use (22). Aside from problems with executive function skills like working memory, initiation, mental flexibility, inhibition, self-monitoring, and emotional control, research suggests that anabolic steroid use may be associated with a higher risk of mental health problems like depression, aggression, and self-harm (23). For instance, Hauger et al.’s research (24), which included 44 participants, revealed that 22.7% (10 out of 44) of them reported an increase in aggressiveness that they blamed on AAS use. According to Hauger et al., those dependent on AAS had lower IQ scores and more signs of Attention Deficit Hyperactivity Disorder (ADHD). ADHD symptoms were significantly positively correlated with self-reported issues with EFs and psychological distress. According to these results, AAS dependence is linked to lower EFs and psychological distress (25). According to Hauger et al., people who depend on AAS should be checked for mental health problems and given advice on how to reduce their potential risk. The risk of developing violent and aggressive behavior may rise when anabolic androgenic steroids (AAS) are used (26). According to Murray et al., the relationship between AAS use and aggression may be mediated by antisocial personality traits and substance abuse. AAS-related outcomes are shown to include a wide range of issues, such as eating disorders, muscle dysmorphia (27), executive function deficits, affective resilience, depression, suicidal thoughts, cardiovascular and liver issues (28), decreased serotonin neurotransmission, confusion and delirium, manic or hypomanic episodes, and difficulty recognizing emotions (29). The hypothalamic-pituitary-adrenal (HPA) axis, brain-derived neurotrophic factor (BDNF) levels, and androgen receptor activation may all play a role in mediating these negative effects (27). They may also be mediated by impaired emotional processing, which may be a symptom of more serious issues like abnormalities in brain structure and cognition (30). In order to fully comprehend the connection between anabolic steroid use and mental health and to identify potential risk factors and protective factors that may affect this relationship, it is important to note that more research is required. Future research on the treatment of anabolic steroid withdrawal depression and other potential side effects associated with the use of these medications is needed, even though Malone et al. identified that anabolic steroid withdrawal depression can be treated with antidepressant medications, in the case of this study specifically fluoxetine (31). Studies to pinpoint better therapies and ascertain the long-term effects of anabolic steroid use on mental health may fall under this category. In order to identify potential preventative measures, it may also be helpful to look into the underlying mechanisms that lead to the emergence of anabolic steroid withdrawal depression and other mental health problems. In order to lessen the potential drawbacks of these drugs, research may also concentrate on creating methods to decrease the prevalence of anabolic steroid use, particularly among young people. Overall, our research showed that steroid use is linked to a number of negative effects on mental health, such as a higher risk of depression, anxiety, and aggression. These results imply that additional study is required to comprehend the mechanisms underlying these effects and to create preventative and therapeutic strategies for steroid-related mental health issues. ## Discussion According to the findings of this systematic review, bodybuilders and fitness athletes may be more susceptible to developing muscle dysmorphia, having disordered eating habits, and using performance-enhancing drugs like anabolic-androgenic steroids (AAS). One significant factor is the COVID-19 pandemic’s increased reliance on social media and online interactions, which has been associated with disordered eating patterns and negative body image in earlier studies. Additionally, being a member of a sexual minority may increase one’s risk of developing muscle dysmorphia and other types of BDD because these people may experience additional stressors and difficulties due to stigma and discrimination, which may worsen one’s sense of self and body image. A greater number of sexual partners, getting older, and having higher levels of impulsivity and eating concern have also been found to be associated with higher levels of muscle dysmorphia and related behaviors. It is crucial to keep researching these variables in order to comprehend how they might influence the emergence of muscle dysmorphia and the use of AAS and other performance-enhancing substances. It is crucial to understand that AAS do not treat muscle dysmorphia and may even exacerbate the condition. AAS use can have a number of harmful effects on the body, including psychiatric disorders, liver damage, and cardiovascular issues (32,33). It is essential for people with muscle dysmorphia to get the right treatment, like cognitive-behavioral therapy, which can assist them in addressing the root causes of their condition and learning coping mechanisms for dealing with their distress. Given that many of the primary causes of male morbidity and mortality are avoidable health behaviors, lifestyle medicine is essential to men’s health. It is important to understand how gender socialization and masculinity affect men’s health risk and protective behaviors in order to effectively address men’s health issues. Many people are now more stressed, anxious, and isolated as a result of the COVID-19 pandemic, which has had a significant effect on mental health. These factors can contribute to an increased risk of substance use and BDD, as people may turn to substances or unhealthy behaviors as a means of coping with the added stress and uncertainty. In order to address these conditions effectively, it is important for individuals to seek out appropriate treatment and support. This may entail enlisting the aid of mental health specialists like therapists or psychiatrists as well as engaging in self-help techniques like looking for social support and learning relaxation methods. To address the underlying causes of BDD and related conditions, broader societal changes are necessary in addition to individual treatment methods. In doing so, it may be necessary to address the stigma associated with mental health conditions as well as societal pressures relating to body image and appearance. It’s crucial to acknowledge the significant effects that BDD and related conditions can have on a person’s relationships and social connections. People should consider joining support groups or looking for other forms of social support in addition to asking their friends and family for support. Understanding how gender socialization and masculinity influence men’s health risk and protective behaviors is crucial for addressing the effects of BDD and related conditions on men’s health. This may involve addressing societal expectations and norms related to masculinity, as well as providing education and resources to help men make informed health decisions. Overall, it is clear that BDD, muscle dysmorphia, and other related mental health conditions can have significant impacts on individuals’ physical and mental health. It is important for individuals to seek out appropriate treatment and support in order to manage these conditions effectively, and for broader societal changes to address the root causes of these conditions. ## Conclusion In summary, this systematic review has uncovered a number of variables that may be linked to an elevated risk of muscle dysmorphia, disordered eating behaviors, and use of performance-enhancing drugs, including AAS, in bodybuilders and fitness athletes. There are a number of areas where further research could be beneficial in improving our understanding of muscle dysmorphia and related behaviors among bodybuilders and fitness athletes. Additional factors, such as having more sexual partners, getting older, having higher levels of eating concern and impulsivity, and having more of them, could also be looked into to better understand their role in the emergence and maintenance of muscle dysmorphia and related behaviors. To better understand their role in the emergence and maintenance of muscle dysmorphia and related behaviors, additional factors could also be investigated. Future research may also focus on the creation and assessment of interventions for at-risk individuals, such as cognitive-behavioral therapy, mindfulness-based interventions, and peer support programs. Long-term studies could look at the impact of muscle dysmorphia and related behaviors on physical and mental health as well as the effectiveness of different interventions in reducing the risk of these behaviors and improving general health outcomes. These findings have important implications for practice, policy, and future research. It is important to specifically recommend that people with BDD seek out appropriate care, such as cognitive-behavioral therapy, to address the underlying causes of their condition and learn coping mechanisms for reducing their distress before they turn towards unhealthy outlets, such as AAS. For the purpose of identifying successful interventions and treatments for people who are dealing with these problems, more research is required to better understand the complex relationship between BDD, AAS use, and mental health outcomes. It is important to note that there are a number of limitations to this systematic review that should be considered when interpreting the results. The few studies that met the criteria for inclusion and the likelihood of bias in the studies that were included are two examples of these limitations. In order to provide a more thorough understanding of the relationship between BDD, AAS use, and mental health outcomes, additional research is required to replicate and build upon the findings of this review. ## Data Availability All data produced in the present work are contained in the manuscript ## Acknowledgements None ## Footnotes * **Email addresses** Ahmed Gawash Gawash14{at}rowan.edu Hasan Zia hz423{at}scarletmail.rutgers.edu David F. Lo Lodavi26{at}rowan.edu * **Funding:** No funding was received for this study/paper. * **Competing interests:** The authors declare that they have no competing interests. ## Abbreviations * Received January 14, 2023. * Revision received January 14, 2023. * Accepted January 17, 2023. * © 2023, Posted by Cold Spring Harbor Laboratory The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission. ## References 1. 1.Nicewicz HR, Boutrouille JF. Body Dysmorphic Disorder. In: StatPearls. Treasure Island (FL): StatPearls Publishing; September 28, 2022. 2. 2.Singh AR, Veale D. Understanding and treating body dysmorphic disorder. Indian J Psychiatry. 2019;61(Suppl 1):S131–S135. doi:10.4103/psychiatry.IndianJPsychiatry\_528\_18 [CrossRef](http://medrxiv.org/lookup/external-ref?access\_num=10.4103/psychiatry.IndianJPsychiatry_528_18&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=30745686&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F01%2F17%2F2023.01.14.23284562.atom) 3. 3.Phillips KA. Body dysmorphic disorder: recognizing and treating imagined ugliness. World Psychiatry. 2004;3(1):12–17. [PubMed](http://medrxiv.org/lookup/external-ref?access_num=16633443&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F01%2F17%2F2023.01.14.23284562.atom) 4. 4.Bjornsson AS, Didie ER, Phillips KA. Body dysmorphic disorder. Dialogues Clin Neurosci. 2010;12(2):221–232. doi:10.31887/DCNS.2010.12.2/abjornsson [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.31887/DCNS.2010.12.2/abjornsson&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=20623926&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F01%2F17%2F2023.01.14.23284562.atom) 5. 5.Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med. 2004;34(8):513–554. doi:10.2165/00007256-200434080-00003 [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.2165/00007256-200434080-00003&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=15248788&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F01%2F17%2F2023.01.14.23284562.atom) [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000222937700003&link_type=ISI) 6. 6.Foster AC, Shorter GW, Griffiths MD. Muscle dysmorphia: could it be classified as an addiction to body image?. J Behav Addict. 2015;4(1):1–5. doi:10.1556/JBA.3.2014.001 [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1556/JBA.3.2014.001&link_type=DOI) 7. 7.NIDA. Introduction. National Institute on Drug Abuse website. [https://nida.nih.gov/publications/research-reports/steroids-other-appearance-performance-enhancing-drugs-apeds/introduction](https://nida.nih.gov/publications/research-reports/steroids-other-appearance-performance-enhancing-drugs-apeds/introduction). August 3, 2021 Accessed January 10, 2023. 8. 8.Nelson BS, Hildebrandt T, Wallisch P. Anabolic-androgenic steroid use is associated with psychopathy, risk-taking, anger, and physical problems. Sci Rep. 2022;12(1):9133. doi:10.1038/s41598-022-13048-w [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41598-022-13048-w&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=35650220&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F01%2F17%2F2023.01.14.23284562.atom) 9. 9.Griffiths S, Jacka B, Degenhardt L, Murray SB, Larance B. Physical appearance concerns are uniquely associated with the severity of steroid dependence and depression in anabolic-androgenic steroid users. Drug Alcohol Rev. 2018;37(5):664–670. doi:10.1111/dar.12688 [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1111/dar.12688&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=29484740&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F01%2F17%2F2023.01.14.23284562.atom) 10. 10.Jenkins Z, Castle D. Body dysmorphia in boys and young men. Medicine Today. 2021;22(6):57–59. 11. 11.Iff S, Frohlich S, Halioua R, Imboden C, Sporri J, Scherr J, et al. Training Patterns and Mental Health of Bodybuilders and Fitness Athletes During the First Lockdown of the COVID-19 Pandemic—A Cross-Sectional Study.Front. sports act. living. 2022;4. doi: 10.3389/fspor.2022.867140 [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.3389/fspor.2022.867140&link_type=DOI) 12. 12.Garfield CF, Isacco A, Rogers TE. A Review of Men’s Health and Masculinity. Am. J. Lifestyle Med. 2008;2(6):474–487. doi: 10.1177/1559827608323213 [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1177/1559827608323213.&link_type=DOI) 13. 13.Zaami S, Sirignano A, Garcia-Algar O. COVID-19 pandemic, substance use disorders and body image issues, a worrisome correlation. Eur Rev Med Pharmacol Sci. 2022;26(1):291–297. doi: 10.26355/eurrev\_202201\_27780 [CrossRef](http://medrxiv.org/lookup/external-ref?access\_num=10.26355/eurrev_202201_27780&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=35049007&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F01%2F17%2F2023.01.14.23284562.atom) 14. 14.Koran LM, Abujaoude E, Large MD, Serpe RT. The prevalence of body dysmorphic disorder in the United States adult population. CNS Spectr. 2008;13: 316–322. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1017/S1092852900016436&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=18408651&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F01%2F17%2F2023.01.14.23284562.atom) [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000255381400013&link_type=ISI) 15. 15.Veale D, Gledhill LJ, Christodoulou P, Hodsoll J. Body dysmorphic disorder in different settings: A systematic review and estimated weighted prevalence. Body Image 2016;18: 168–186. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.bodyim.2016.07.003&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=27498379&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F01%2F17%2F2023.01.14.23284562.atom) 16. 16.Nagata JM, Compte EJ, Cattle CJ, Lavender JM, Brown TA, Murray SB, et al. Community norms of the Muscle Dysmorphic Disorder Inventory (MDDI) among cisgender sexual minority men and women. BMC Psychiatry. 2021;21(1):297. doi: 10.1186/s12888-021-03302-2 [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1186/s12888-021-03302-2&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=34103034&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F01%2F17%2F2023.01.14.23284562.atom) 17. 17.Nagata JM, DeBenedetto AM, Brown TA, et al. Associations among romantic and sexual partner history and muscle dysmorphia symptoms, disordered eating, and appearance- and performance-enhancing drugs and supplement use among cisgender gay men. Body Image. 2022;41:67–73. doi:10.1016/j.bodyim.2022.02.004 [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.bodyim.2022.02.004&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=35228105&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F01%2F17%2F2023.01.14.23284562.atom) 18. 18.Strubel J, Leger R, Guan X. Appearance and performance enhancing drug usage and body image across three age cohorts of fitness enthusiast men. JOMH. 2022; 18(2):51. doi: 10.31083/J.JOMH1802051 [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.31083/J.JOMH1802051&link_type=DOI) 19. 19.Klimek P, Hildebrandt T. Psychosocial correlates of gap time to anabolic-androgenic steroid use. Int J Eat Disord. 2018;51(6):535–541. doi:10.1002/eat.22859 [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/eat.22859&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=29542171&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F01%2F17%2F2023.01.14.23284562.atom) 20. 20.Hildebrandt T, Alfano L, Langenbucher JW. Body image disturbance in 1000 male appearance and performance enhancing drug users. J Psychiatr Res. 2010;44(13):841–846. doi:10.1016/j.jpsychires.2010.01.001 [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.jpsychires.2010.01.001&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=20110092&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F01%2F17%2F2023.01.14.23284562.atom) 21. 21.Ghaderi A, Welch E. Appearance and Performance-Enhancing Drugs and Supplements, Eating Disorders Symptoms, Drive for Muscularity, and Sexual Orientation in a Sample of Young Men. Nutrients. 2022;14(22):4920. Published 2022 Nov 21. doi:10.3390/nu14224920 [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.3390/nu14224920&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=36432606&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F01%2F17%2F2023.01.14.23284562.atom) 22. 22.Piacentino D, Kotzalidis GD, Del Casale A, et al. Anabolic-androgenic steroid use and psychopathology in athletes. A systematic review. Curr Neuropharmacol. 2015;13(1):101–121. doi:10.2174/1570159X13666141210222725 [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.2174/1570159X13666141210222725&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=26074746&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F01%2F17%2F2023.01.14.23284562.atom) 23. 23.Nackeeran S, Patel MS, Nallakumar DT, et al. Testosterone Therapy is Associated With Depression, Suicidality, and Intentional Self-Harm: Analysis of a National Federated Database. J Sex Med. 2022;19(6):933–939. doi:10.1016/j.jsxm.2022.03.611 [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.jsxm.2022.03.611&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=35437187&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F01%2F17%2F2023.01.14.23284562.atom) 24. 24.Lykhonosov MP, Babenko AY, Makarin VA, Fedotov YN. Probl Endokrinol (Mosk). 2019;65(5):341–350. Published 2019 Nov 23. doi:10.14341/probl12108 [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.14341/probl12108&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32202738&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F01%2F17%2F2023.01.14.23284562.atom) 25. 25.Hauger LE, Westlye LT, Bjørnebekk A. Anabolic androgenic steroid dependence is associated with executive dysfunction. Drug Alcohol Depend. 2020;208:107874. doi:10.1016/j.drugalcdep.2020.107874 [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.drugalcdep.2020.107874&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=31972519&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F01%2F17%2F2023.01.14.23284562.atom) 26. 26.Hauger LE, Havnes IA, Jørstad ML, Bjørnebekk A. Anabolic androgenic steroids, antisocial personality traits, aggression and violence. Drug Alcohol Depend. 2021;221:108604. doi:10.1016/j.drugalcdep.2021.108604 [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.drugalcdep.2021.108604&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=33621808&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F01%2F17%2F2023.01.14.23284562.atom) 27. 27.Murray SB, Griffiths S, Mond JM, Kean J, Blashill AJ. Anabolic steroid use and body image psychopathology in men: Delineating between appearance-versus performance-driven motivations. Drug Alcohol Depend. 2016;165:198–202. doi:10.1016/j.drugalcdep.2016.06.008 [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.drugalcdep.2016.06.008&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=27364377&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F01%2F17%2F2023.01.14.23284562.atom) 28. 28.Matrisciano F, Modafferi AM, Togna GI, et al. Repeated anabolic androgenic steroid treatment causes antidepressant-reversible alterations of the hypothalamic-pituitary-adrenal axis, BDNF levels and behavior. Neuropharmacology. 2010;58(7):1078–1084. doi:10.1016/j.neuropharm.2010.01.015 [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.neuropharm.2010.01.015&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=20138062&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F01%2F17%2F2023.01.14.23284562.atom) [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000277475900014&link_type=ISI) 29. 29.Khoodoruth MAS, Khan AA. Anabolic steroids-induced delirium: A case report. Medicine (Baltimore). 2020;99(33):e21639. doi:10.1097/MD.0000000000021639 [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1097/MD.0000000000021639&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32872027&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F01%2F17%2F2023.01.14.23284562.atom) 30. 30.Hauger LE, Sagoe D, Vaskinn A, et al. Anabolic androgenic steroid dependence is associated with impaired emotion recognition. Psychopharmacology (Berl). 2019;236(9):2667–2676. doi:10.1007/s00213-019-05239-7 [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s00213-019-05239-7&link_type=DOI) 31. 31.Malone DA Jr., Dimeff RJ. The use of fluoxetine in depression associated with anabolic steroid withdrawal: a case series. J Clin Psychiatry. 1992;53(4):130–132. [PubMed](http://medrxiv.org/lookup/external-ref?access_num=1564048&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F01%2F17%2F2023.01.14.23284562.atom) [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=A1992HQ26700004&link_type=ISI) 32. 32.Liu JD, Wu YQ. Anabolic-androgenic steroids and cardiovascular risk. Chin Med J (Engl). 2019;132(18):2229–2236. doi:10.1097/CM9.0000000000000407 [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1097/CM9.0000000000000407&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=31478927&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F01%2F17%2F2023.01.14.23284562.atom) 33. 33.Albano GD, Amico F, Cocimano G, et al. Adverse Effects of Anabolic-Androgenic Steroids: A Literature Review. Healthcare (Basel). 2021;9(1):97. Published 2021 Jan 19. doi:10.3390/healthcare9010097 [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.3390/healthcare9010097&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=33477800&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F01%2F17%2F2023.01.14.23284562.atom)